A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC) with brain metastases to determine the best option for treatment. Stereotactic radiosurgery, in combination with targeted therapy using EGFR tyrosine kinase inhibitors, resulted in the longest survival and best outcomes for patients.

The association between provider case volume and outcomes has long been suggested in cancer care. A Yale Cancer Center team has completed a review of outcomes for patients with locally advanced squamous cell head and neck cancers treated with intensity-modulated radiation therapy (IMRT) and found a distinct association between higher-volume treatment centers and improved overall survival. The findings were presented Sept. 26 at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting in Boston.

RaySearch demonstrated new features in the upcoming release of its proprietary treatment planning system, RayStation, during the 2016 annual meeting of the American Society for Radiation Oncology (ASTRO), Sept. 25-28 in Boston. In addition, the company also exhibited its oncology information system, RayCare, which is under development and due to be launched in the second half of 2017.

Analogic Corp. announced last week that it will introduce its new premium cardiac imaging software for the bk3500 ultrasound system at the American College of Emergency Physicians (ACEP) Scientific Assembly, Oct. 16–19, 2016, in Las Vegas.

Lantheus Holdings Inc. announced in late September that sub-analysis data from the first Phase 3 study of flurpiridaz F-18 for myocardial perfusion imaging (MPI) in patients undergoing exercise stress testing. The data was presented at the 21st annual scientific session of the American Society of Nuclear Cardiology (ASNC), Sept. 22-25 in Boca Raton, Fla.

Breast cancer death rates among women decreased during 2010-2014, but racial differences persisted, according to a study by the Centers for Disease Control and Prevention (CDC) in this week’s Morbidity and Mortality Weekly Report.

In the largest trial conducted for average risk (A-R) medulloblastoma, survival rates following reduced radiation therapy (RT) boost volumes were comparable to standard treatment volumes for the primary tumor site. However, lower doses of craniospinal axis irradiation were associated with higher event rates and worse survival, according to research presented at the 58th annual meeting of the American Society for Radiation Oncology (ASTRO), Sept. 25-28 in Boston.